Ephedra: Experts Speak Out On The Good, The Bad And The Ugly

Left to its own devices FDA might not conduct a new risk/benefit analysis; however, a citizen petition asking for an analysis of an herb could spur FDA to action, Attorney Marc Ullman told "The Tan Sheet."